Pfizer Inc. (NYSE: PFE) released today its 2015 integrated annual
review, an in-depth look into the company’s financial, social and
environmental performance. 2015 was marked by breakthrough scientific
research, collaborations and partnerships. In the review, our
scientists, researchers and business leaders offer in-depth looks at
their projects and how they are working to discover and develop
potential new medicines and vaccines to improve patient health.
“Our purpose at Pfizer is to bring therapies to patients that
significantly improve their lives,” said Pfizer Chairman and Chief
Executive Officer Ian C. Read. “Thanks to the more than 97,000 Pfizer
colleagues around the world, we met our yearly commitments and continued
to build the company's capabilities toward our goal to become the
world's premier, innovative biopharmaceutical company by the end of this
decade.”
As a result of our research as well as innovative collaborations with
our peers and research partners, we saw great scientific progress across
multiple therapeutic areas in 2015.
-
We advanced 39 potential new therapies in our R&D pipeline,
representing the strongest progress in Pfizer's history.
-
Our research efforts in oncology have resulted in a broad and deep
portfolio of compounds, including five immuno-oncology assets in human
studies that have the potential to address the urgent therapeutic
needs of cancer patients.
-
We advanced our investigational vaccines pipeline to research some of
the most deadly infectious diseases that affect people of all ages.
In 2015, Pfizer made great strides to help ensure patients around the
world have access to the Pfizer medicines and vaccines that are approved
and available. “Our very license to operate depends on ensuring the
medicines we make to improve patient health and wellbeing are available
to as many people as possible,” commented Sally Susman, Executive Vice
President, Corporate Affairs. “Patient assistance is not a program or
catchphrase, it is a commitment.”
-
In 2015, we significantly expanded the eligibility of our U.S. patient
assistance program, Pfizer RxPathways®. The program helped
more than 250,000 people access our medicines during the year.
-
We continued global health partnerships including the International
Trachoma Initiative at The Task Force for Global Health, which seeks
to eliminate the world's leading cause of preventable blindness and
marked 2015 with the 500 millionth dose donation of antibiotic
Zithromax® (azithromycin).
-
2015 was the 5th year of our partnership with Gavi, the
Vaccine Alliance, in which we have pledged 740M doses of pneumococcal
vaccines to immunize children in GAVI countries through 2025.
-
To address family planning needs of women in the developing world, our
collaboration with the Bill & Melinda Gates Foundation and the
Children's Investment Fund Foundation (CIFF) completed its first-full
year, and was successful in helping broaden access to injectable
contraceptive, Sayana® Press (medroxyprogesterone acetate), to tens of
thousands of women across several countries in Africa and Asia.1
Hear directly from our scientists, researchers and business leaders in
our annual review: www.pfizer.com/annual
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of healthcare products. Our global portfolio
includes medicines and vaccines as well as many of the world's
best-known consumer healthcare products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world's
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. For more information, please visit us at www.pfizer.com.
In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and
like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release
is as of March 15, 2016. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result of
new information or future events or developments.
This release contains forward-looking information that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, the uncertainties
inherent in research and development; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2015 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned "Risk Factors" and "Forward-Looking
Information and Factors That May Affect Future Results", as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and
www.pfizer.com.
_______________________________
1 PATH/CIFF data on file
View source version on businesswire.com: http://www.businesswire.com/news/home/20160315006565/en/
Copyright Business Wire 2016